Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in...
Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients...
Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with...
Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to...
Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better...
Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in...
Media Release SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results...
Media Release Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the...
Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell...
Media Release SYDNEY, AUSTRALIA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지